ECDC and the European Respiratory Society (ERS) have developed 21 patient-centred standards that aim to guide clinicians and public health workers in their daily work to ensure optimal diagnosis, treatment and prevention of tuberculosis (TB) in Europe. Nearly 74 000 reported TB cases in the EU/EEA in 2010 clearly show that tuberculosis remains a public health challenge across the region.
In a hearing at the European Parliament in Brussels, ECDC Director Marc Sprenger underlined the importance of sufficient resources at national level to diagnose and adequately treat tuberculosis.
To mark World Tuberculosis Day on 24 March 2012, the European Centre for Disease Prevention and Control (ECDC) and the WHO Regional Office for Europe publish their joint report, Tuberculosis surveillance and monitoring in Europe 2012.
In a recent scientific article (Udwadia, F et al. Clin. Infect. Dis. 2011, Dec 21, Eprint) four cases of so-called total drug resistant tuberculosis (TB) were reported from India.
On the occasion of the European Respiratory Society’s (ERS) Annual Congress in Amsterdam, ECDC and ERS today introduce a draft of the EU Standards for Tuberculosis Care (ESTC).
The WHO Regional Committee for Europe approved a new action plan to tackle multi-drug resistant and extensively drug resistant tuberculosis (M/XDR-TB) today. This is another milestone in the European efforts to secure strong tuberculosis prevention and control across the region.
ECDC was pleased that the Government of Romania extended an invite to meet health care workers who are working with the Roma population. ECDC Director, Marc Sprenger, as head of the delegation shares three lesson.
During a recent country visit to Romania, ECDC emphasised the key issues for TB control. Following the invitation of the Romania Ministry of Health, ECDC disease experts, led by ECDC Director Marc Sprenger, visited the Marius Nasta Institute, which historically has been in the front line for TB control in the country.
IGRAs are increasingly being considered for the diagnosis of LTBI, as a replacement to the TST, including travel medicine. As with the TST, many uncertainties remain with regard to the efficacy of the IGRAs. It is therefore essential to secure an accurate understanding of these assays‘ known efficacy, so that they be optimally used and only in context with proven effect.
A new report, Tuberculosis surveillance in Europe 2009, a joint publication from ECDC and the WHO Regional Office for Europe to mark World Tuberculosis Day 2011, provides evidence for concern about the spread of multi-drug resistant tuberculosis (MDR TB) and the persistence of TB among children.